The study aims to investigate the efficacy and safety of a drug in patients with moderately to severely active rheumatoid arthritis.
Up to 50 investigational sites will take part in the clinical trial. At the moment, two-thirds of the total number of patients have been enrolled. All patients will be randomized in one of three treatment groups. The planned duration of treatment is 24 weeks.
Phase III clinical trials comprise the biggest part of our portfolio. The OCT team undertakes all activities related to site selection and management, regulatory support, project management, data management, etc.